115 related articles for article (PubMed ID: 32164353)
1. Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family.
Sadzevičienė I; Jarmalaitė S; Besusparis J; Liaugaudienė O; Asadauskienė J; Brasiūnienė B; Kulikienė I; Sabaliauskaitė R
Medicina (Kaunas); 2020 Mar; 56(3):. PubMed ID: 32164353
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling.
Palmieri G; Palomba G; Cossu A; Pisano M; Dedola MF; Sarobba MG; Farris A; Olmeo N; Contu A; Pasca A; Satta MP; Persico I; Carboni AA; Cossu-Rocca P; Contini M; Mangion J; Stratton MR; Tanda F
Ann Oncol; 2002 Dec; 13(12):1899-907. PubMed ID: 12453858
[TBL] [Abstract][Full Text] [Related]
3. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
Marchina E; Fontana MG; Speziani M; Salvi A; Ricca G; Di Lorenzo D; Gervasi M; Caimi L; Barlati S
Oncol Rep; 2010 Dec; 24(6):1661-7. PubMed ID: 21042765
[TBL] [Abstract][Full Text] [Related]
5. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
[TBL] [Abstract][Full Text] [Related]
6. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
[TBL] [Abstract][Full Text] [Related]
7. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Antoniou A; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Loman N; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
Am J Hum Genet; 2003 May; 72(5):1117-30. PubMed ID: 12677558
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME
Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
Janavičius R; Rudaitis V; Mickys U; Elsakov P; Griškevičius L
Cancer Genet; 2014 May; 207(5):195-205. PubMed ID: 25066507
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM
Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Meindl A;
Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
[TBL] [Abstract][Full Text] [Related]
12. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
14. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
[TBL] [Abstract][Full Text] [Related]
15. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
[TBL] [Abstract][Full Text] [Related]
16. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI
BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160
[TBL] [Abstract][Full Text] [Related]
17. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
[TBL] [Abstract][Full Text] [Related]
18. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG
Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204
[TBL] [Abstract][Full Text] [Related]
19. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
Mann GJ; Thorne H; Balleine RL; Butow PN; Clarke CL; Edkins E; Evans GM; Fereday S; Haan E; Gattas M; Giles GG; Goldblatt J; Hopper JL; Kirk J; Leary JA; Lindeman G; Niedermayr E; Phillips KA; Picken S; Pupo GM; Saunders C; Scott CL; Spurdle AB; Suthers G; Tucker K; Chenevix-Trench G;
Breast Cancer Res; 2006; 8(1):R12. PubMed ID: 16507150
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece.
Triantafyllidou O; Vlachos IS; Apostolou P; Konstantopoulou I; Grivas A; Panopoulos C; Dimitrakakis C; Kassanos D; Loghis C; Bramis I; Vlahos N; Yannoukakos D; Fostira F
J BUON; 2015; 20(4):978-84. PubMed ID: 26416046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
